8-K: Dare Bioscience Regains Ovaprene Rights, Phase 3 Continues

Dare Bioscience announced Bayer's termination of their Ovaprene license agreement, returning full commercialization rights to Dare while its Phase 3 study progresses with positive interim data and grant funding.

Summary

• Bayer HealthCare LLC terminated the license agreement for Ovaprene with Dare Bioscience, effective February 24, 2026, due to Bayer's strategic prioritization.
• Dare Bioscience will not receive any future license fees, milestone, or other payments from Bayer, and all licenses and rights granted to Bayer will terminate.
• Dare Bioscience previously received a $1.0 million upfront non-refundable license fee from Bayer, which will be recorded as license revenue upon termination.
• The termination is not expected to materially impact the ongoing pivotal Phase 3 clinical study of Ovaprene (ClinicalTrials.gov ID: NCT06127199).
• In July 2025, the study's Data Safety Monitoring Board (DSMB) conducted a planned interim analysis and recommended the study continue without modification.
• Data collected through September 15, 2025, and reported to the FDA, was consistent with the DSMB's findings regarding safety, tolerability, and pregnancy experiences.
• Dare Bioscience intends to maintain active recruitment at five study sites, supported by grant funding received in November 2024.
• Enrollment in the Phase 3 study is currently anticipated to be completed in 2026.

Sentiment

Score: 7

Explanation: While the termination of a partnership is generally negative, the filing emphasizes the strategic benefits of regaining full rights to a promising late-stage asset, coupled with positive interim clinical data and non-dilutive funding, suggesting a net positive outlook for Ovaprene's future development and commercialization potential.

Positives

• Dare Bioscience regains full global commercialization rights to Ovaprene, a late-stage asset, providing maximum strategic flexibility.
• The Phase 3 clinical study for Ovaprene is progressing without material impact from the termination and is supported by non-dilutive grant funding, including an award from the Gates Foundation.
• Positive interim data from the Phase 3 trial in July 2025 demonstrated encouraging results, including consistent safety and tolerability, with no serious safety concerns identified.
• The rate of pregnancy in the study at the time of interim analysis was consistent with company expectations, reinforcing Ovaprene's clinical and commercial potential.
• Ovaprene has the potential to become the first FDA-approved hormone-free, monthly intravaginal contraceptive option, addressing a significant unmet need in women's health.
• The company believes that Ovaprene will attract broad strategic interest across pharmaceutical and consumer health organizations for future partnerships.

Negatives

• Termination of the license agreement with Bayer HealthCare LLC.
• Loss of future license fees, milestone, or other payments from Bayer.
• Loss of Bayer's agreed-upon support in development and regulatory activities, which included the equivalent of two experts.

Risks

• Ability to design and conduct successful clinical trials, enroll sufficient patients, meet established clinical endpoints, avoid undesirable side effects, and demonstrate sufficient safety and efficacy of product candidates.
• Dependence on third parties to conduct clinical and nonclinical studies and manufacture and supply clinical trial material and commercial product.
• Positive findings in early clinical and/or nonclinical studies may not be predictive of success in subsequent studies, and interim data may not predict final results.
• The FDA, other regulatory authorities, or the scientific/medical communities may not accept or agree with Dare's interpretation of or conclusions regarding clinical study data.
• Development of a product candidate may require more clinical or nonclinical studies, or studies of greater duration or with more subjects, than anticipated.
• Ability to raise additional capital when and as needed to execute business strategy and continue as a going concern.
• Dependence on grants and other financial awards from governmental entities and the Gates Foundation, and the foundation's ability to modify, suspend, discontinue, or terminate grant agreements.
• Limitations on ability to raise additional capital through sales of common stock or other equity securities due to SEC and Nasdaq rules or contractual limitations.
• Inexperience and lack of infrastructure for commercializing products.
• Degree of market demand and acceptance for products brought to market and competitive product launches.
• Ability to identify, develop, obtain FDA or foreign regulatory approval for, and commercialize product candidates on communicated timelines.
• Failure or delay in starting, conducting, or completing clinical trials and the inherent uncertainty of outcomes.
• Loss of, or inability to attract, key personnel.
• Ability to retain licensed rights to develop and commercialize a product or product candidate.
• Ability to satisfy monetary obligations and other requirements in connection with exclusive in-license agreements covering critical patents and related intellectual property.
• Ability to adequately protect or enforce its, or its licensors', intellectual property rights, and disputes or other developments concerning intellectual property rights.
• Product pricing and coverage and reimbursement from third-party payors.
• Product liability claims and governmental investigations or actions relating to products or business activities.
• Changes in healthcare, pharmaceutical, consumer protection, or privacy laws and regulatory policies, and increased scrutiny from regulators.
• Global trends toward healthcare cost containment.
• Effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on capital raising, operations, financial results, and ability to achieve plans.
• Ability to maintain compliance with Nasdaq's continued listing requirements.
• Cybersecurity incidents or similar events that compromise technology systems and/or significantly disrupt business or those of third parties relied upon.

Future Outlook

Dare Bioscience anticipates completing enrollment in the Ovaprene Phase 3 study in 2026 and plans to provide further updates on enrollment and study completion targets. The company expects the termination of the Bayer license agreement to not materially impact the ongoing Phase 3 study, which continues with non-dilutive grant funding. With full commercialization rights returned, Dare intends to evaluate partnership structures to maximize the value of Ovaprene, believing it will attract broad strategic interest across pharmaceutical and consumer health organizations.

Management Comments

• "We view the consolidation of commercial rights under Dar at this stage of Ovaprenes development as value-enhancing for our company." Sabrina Martucci Johnson, President and CEO of Dar Bioscience.
• "The Phase 3 study is progressing, supported by non-dilutive funding, and the positive interim data announced in July 2025 underscore the assets potential. We will have maximum strategic flexibility to capture the value of this opportunity." Sabrina Martucci Johnson.
• "We believe this development gives us the ability to pursue the most attractive commercial and access pathways for Ovaprene, including partnerships, non-traditional commercialization models, and opportunities to retain greater long-term economics." Sabrina Martucci Johnson.
• "This increased optionality, combined with the clinical profile demonstrated to date, positions Ovaprene as one of the most exciting assets in the womens health pipeline." Sabrina Martucci Johnson.

Industry Context

The women's health sector, particularly in contraception, has seen limited innovation for decades. Ovaprene, as an investigational hormone-free monthly intravaginal contraceptive, aims to address a significant unmet need by offering a first-in-category option. The return of full commercialization rights to Dare Bioscience positions the company to potentially disrupt this market with a differentiated late-stage asset, attracting interest from both pharmaceutical and consumer health organizations seeking novel solutions in a growing area of focus.

Comparison to Industry Standards

• Ovaprene has the potential to become the first FDA-approved hormone-free, monthly intravaginal contraceptive option, representing a meaningful innovation in a category that has seen limited advancement in decades.
• Unlike current FDA-approved monthly intravaginal contraceptives, Ovaprene does not contain hormones.
• Consistent with other monthly intravaginal contraceptives, Ovaprene is designed to be a one-size-fits-most, monthly, self-administered product requiring no action at intercourse and no clinician fitting.

Stakeholder Impact

• Shareholders: Potential for increased value from full control over a late-stage asset and strategic flexibility; however, there is a risk of needing to raise additional capital.
• Patients/Customers: Continued development of a potential first-in-category hormone-free contraceptive option.
• Employees: Continued progression of the Ovaprene program.
• Partners (future): Increased optionality for new commercialization partnerships.

Next Steps

• Complete enrollment in the Ovaprene Phase 3 study in 2026.
• Provide further updates regarding anticipated enrollment and study completion targets in 2026.
• Maintain active recruitment at five study sites for the Ovaprene Phase 3 study.
• Evaluate partnership structures and explore strategic transaction opportunities for Ovaprene.
• Pursue a Premarket Approval (PMA) strategy with the FDA's Center for Devices and Radiological Health (CDRH).

Key Dates

Recommendation

The termination of the Bayer license agreement introduces uncertainty and removes a significant partner, which is a negative. However, the company has regained full rights to a promising late-stage asset (Ovaprene) with positive interim Phase 3 data and non-dilutive funding. This provides strategic flexibility for future commercialization. The stock is likely to experience volatility due to the news, but the underlying asset's potential remains. A 'hold' recommendation allows investors to observe how Dare Bioscience executes its new commercialization strategy and progresses the Phase 3 trial without the Bayer partnership, balancing the immediate negative of the termination with the long-term potential of Ovaprene.

Keywords

Ovaprene, contraceptive, women's health, hormone-free, Phase 3 clinical trial, Bayer, license agreement termination, Dare Bioscience, FDA approval, grant funding, biotech, medical device